Chargement de l’entreprise
Just reported
Q3 2026 results
From Protagonist Therapeutics's results release of 5 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
274,4M $US
+29 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
3,07 $US
+34 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
218,3M $US
+38 % q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Protagonist Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B $USA+
EXELExelixis, Inc.16,8B $USA+
JAZZJazz Pharmaceuticals plc15,5B $USA
TECHBIO-Techne Corp11,4B $USA+
HALOHalozyme Therapeutics, Inc.11,4B $USA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Comment elle gagne de l'argent
- Licensing and collaboration payments
En concurrence avec
Ce qu'elle vend6
Icotyde (icotrokinra)
An oral peptide medicine that blocks the interleukin-23 receptor, a part of the immune system involved in plaque psoriasis. It is approved in the United States for plaque psoriasis and is licensed to Janssen.
Rusfertide
An injected medicine that imitates hepcidin, a natural hormone that regulates iron. It is being reviewed by U.S. regulators as a treatment for polycythemia vera, a rare disease in which the body makes too many red blood cells.
PN-881
An oral peptide medicine that blocks interleukin-17, an immune-system signal involved in inflammatory skin diseases. It is being studied as a possible treatment for psoriasis and related conditions.
Afficher 3 de plus
PN-477
A peptide designed to activate the glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon receptors. It is being developed for obesity in oral and injectable forms.
PN-458
A peptide designed to activate the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. It is being developed for obesity in oral and injectable forms.
PN-8047
An oral small-molecule medicine designed to imitate hepcidin and regulate iron. It is being developed as a possible treatment for polycythemia vera.
Qui l'achète2
- Janssen, part of Johnson & Johnson, pays under the Icotyde licensing and collaboration agreement, including milestone payments and royalties tied to sales.
- Takeda pays under the rusfertide collaboration agreement, including milestone payments and royalties tied to sales.
Sur quoi elle repose, et ce qui pourrait la briser
Ce dont l'activité dépend
- 1Payments from Janssen and Takeda depend on their development, regulatory and commercial work, and some payments depend on approvals or product sales.
- 2Protagonist uses outside companies to manufacture medicines for research and clinical trials; Janssen and Takeda are responsible for manufacturing their partnered medicines.
- 3Drug development and sales depend on approval by the Food and Drug Administration and other regulators, as well as coverage and reimbursement decisions by health insurers and government programs.
- 4The business depends in part on patents, trade secrets and other rights protecting its medicines and drug-discovery methods.
Ce qui pourrait mal tourner
- 1Medicines still in development may fail in clinical studies or may not receive regulatory approval; safety problems could also delay or limit their use.
- 2Revenue depends on partner payments and sales-related royalties. Janssen and Takeda control key development or commercialization work, and future payments depend on events such as approval and sales.
- 3Delays or quality problems at outside clinical-trial providers or manufacturers could interrupt studies or delay the supply of medicines.
À propos de Protagonist Therapeutics, Inc.
Protagonist discovers and develops medicines, including peptide drugs made from short chains of amino acids. It licenses Icotyde to Janssen, part of Johnson & Johnson, which is responsible for its development and commercialization; Protagonist can receive milestone payments and royalties on sales. Takeda has the worldwide rights to develop and commercialize rusfertide, while Protagonist also advances medicines of its own for immune diseases, blood disorders and obesity.
- Siège
- Newark, California
- Fondée en
- 2006
- Effectif
- 141 (June 30, 2026, high)
- Cotée sur
- Nasdaq Global Select Market
- Clôture de l'exercice
- December 31
Construit à partir des documents déposés par Protagonist Therapeutics, Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
